Jesus F. Miguel-San Miguel

Pamplona, NC 31008, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Unpublished overall survival confounders in immunomodulatory agent registrational trials - Authors' reply.

Unpublished overall survival confounders in immunomodulatory agent registrational trials - Authors' reply.

Journal: The Lancet. Oncology
Published: July 01, 2025

Measurable residual disease in multiple myeloma: ready for clinical practice?

Measurable residual disease in multiple myeloma: ready for clinical practice?

Journal: Journal of hematology & oncology
Published: April 07, 2020

Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Journal: Leukemia
Published: March 09, 2019

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature.

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature.

Journal: Blood cancer journal
Published: September 13, 2018

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Journal: Leukemia
Published: April 19, 2017

Is immunotherapy here to stay in multiple myeloma?

Is immunotherapy here to stay in multiple myeloma?

Journal: Haematologica
Published: August 02, 2016

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.

Journal: Advances in therapy
Published: August 01, 2016

Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells.

Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells.

Journal: Cancer cell
Published: September 17, 2015

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.

Journal: Haematologica
Published: March 09, 2015
Showing 1-9 of 9

Last Updated: 09/26/2026